Use of Endometrial Regenerative Cells to Help Avoid Amputation
CALGARY, Aug. 19 /CNW/ - Orcrist Bio Inc. a biotech company developing
stem cell-mobilizing pharmaceuticals, has co-authored a peer reviewed
publication with Medistem Inc. (OTC BB: MEDS.OB) and collaborators at six
academic institutions providing the first preclinical data supporting the
therapeutic efficacy of Medistem's new type of stem cell, called Endometrial
Regenerative Cells (ERC).
The report describes how the administration of ERC's were able to prevent
loss of leg function in an animal equivalent of critical limb ischemia, an
advanced form of peripheral artery disease that leads to more than 100,000
amputations per year. These positive preclinical efficacy data will support
Medistem's efforts at filing FDA reviewed clinical trial applications. The
study was published today in BioMedCentral's open access Journal of
"Orcrist is pleased to have been part of this important study led by
Medistem and the team of internationally renowned vascular and cardiac
surgeons, and hematologists that were assembled," said Gary Voncina, President
and CEO of Orcrist.
"Our collaboration with Orcrist allows us to synergistically address
complex biological problems to both companies' mutual benefit," said Thomas
Ichim, CEO of Medistem. "Orcrist is working on mobilizing the body's stem
cells by pharmaceutical means, while Medistem is generating replacement stem
cells as seen by the development and identification of ERCs."
Orcrist's lead drug product, HYC-750, is capable of expanding and
mobilizing stem cells that are already present in the body, making it
potentially valuable in treating numerous conditions that benefit from
administration of stem cells, including critical limb ischemia.
About Orcrist Bio. Inc.
Orcrist Bio Inc. is a biotechnology company dedicated to developing and
commercializing promising therapeutics for areas in which a clear market
opportunity exists. Orcrist's lead program revolves around HYC750, a novel
stem cell mobilizer compound that promotes the egress of stem cells and other
blood cells from the bone marrow into the blood, from which they can be
harvested and applied toward treating chemotherapy-related white blood cell
depletion. Orcrist is actively looking to add to its pipeline exploring the
innate properties of HYC750 and its effects on stem cells, as well as through
in-licensing opportunities of other products with clear market potential.
Orcrist is located in Calgary, Alberta. The company is financed by its
founders and by private investors. (http://www.orcristbio.com).
About Medistem Inc.
Medistem Inc. is a biotechnology company founded to develop and
commercialize technologies related to adult stem cell extraction,
manipulation, and use for treating inflammatory and degenerative diseases. The
company's lead product, the endometrial regenerative cell (ERC), is a
"universal donor" stem cell derived from the menstrual blood that possesses
the ability to differentiate into nine tissue types, produce large quantities
of growth factors, and a large proliferative capacity. Due to Medistem's
relationships and collaborative efforts with respected institutions, Medistem
believes it is well positioned to be a leading developer of adult stem cell
This document does not constitute an offer to sell or a solicitation of
an offer to buy any of our securities. This document may contain certain
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. Forward-looking statements are inherently subject to risks
and uncertainties, some of which cannot be predicted or quantified. Future
events and actual results could differ materially from those set forth in,
contemplated by, or underlying the forward-looking information.
Factors which may cause actual results to differ from Medistem Inc.'s
forward-looking statements are discussed in its Form 10-K for the year ended
December 31, 2007 as filed with the Securities and Exchange Commission.
For further information:
For further information: